Fractionation studies with WR-2721: normal tissues and tumour.
We have studied the ability of WR-2721 to protect skin, kidney and an anaplastic murine tumour against single or fractionated X-ray treatments. Skin reactions, four different kidney assays, regrowth delay and local control of tumours have been used to construct dose-response curves from which the degree of radioprotection can be quantified as a protection factor. Low doses of WR-2721 (0.2-0.3 mg X g-1) were used before each of 1, 5 or 10 fractions. The degree of protection was similar in all three systems and it did not change significantly with fractionation.
D004999:Amifostine / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D002277:Carcinoma / Q000532:radiotherapy*; D005260:Female; D007668:Kidney / Q000187:drug effects / Q000528:radiation effects; D007928:Lethal Dose 50; D008325:Mammary Neoplasms, Experimental / Q000532:radiotherapy*; D051379:Mice; D008808:Mice, Inbred CBA; D008815:Mice, Inbred Strains; D009946:Organothiophosphorus Compounds / Q000627:therapeutic use*; D011833:Radiation Injuries, Experimental / Q000517:prevention & control*; D011879:Radiotherapy Dosage; D012867:Skin / Q000187:drug effects / Q000528:radiation effects
D009946:Organothiophosphorus Compounds; D004999:Amifostine